CCR5

By Type:	Pan (7) Selective (15)
By Effects:	Inhibitors (8) Antagonists (19)

Cat. No.	Product Name	Effect	Purity

HY-13004

Maraviroc	Antagonist	99.88%
Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV.

HY-13406

TAK-779	Antagonist	99.73%
TAK-779 is a potent and selective nonpeptide antagonist of CCR5 and CXCR3, with a K_i of 1.1 nM for CCR5, and effectively and selectively inhibits R5 HIV-1, with EC₅₀ and EC₉₀ of 1.2 nM and 5.7 nM, respectively, in MAGI-CCR5 cells.

HY-14882

Cenicriviroc	Antagonist	99.01%
Cenicriviroc (TAK-652) is an orally active, dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.

HY-14882A

Cenicriviroc Mesylate	Antagonist	99.04%
Cenicriviroc Mesylate (TAK-652 Mesylate) is a dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.

HY-109593

BMS-813160	Antagonist	99.93%
BMS-813160 is a potent and selective CCR2/5 dual antagonist. BMS-813160 binds with CCR2 and CCR5 with IC₅₀s of 6.2 and 3.6 nM, respectively. BMS-813160 can be used for the research of inflammation.

HY-119658

PF-4178903	Antagonist
PF-4178903 is an orally active, potent dual CCR2 and CCR5 antagonist with IC₅₀ values of 3 nM and 5.3 nM, respectively. PF-4178903 is promising for research of chronic inflammatory and autoimmune diseases.

HY-123902

Ophiobolin C	Inhibitor
Ophiobolin C inhibits CCR5 binding to the envelop protein gp120 and CD4, which is responsible for mediating the entry of HIV-1 into cells. Ophiobolin C is also cytotoxic to chronic lymphocytic leukemia cells.

HY-P4191A

Met-RANTES (human) (acetate)	Antagonist	99.62%
Met-RANTES (human) acetate is the acetate form of Met-RANTES (human) (HY-P4191). Met-RANTES (human) acetate is the antagonist for CCR1 and CCR5. Met-RANTES (human) acetate inhibits chemokines human MIP-1α and MIP-1β with IC₅₀ of 5 and 2 nM. Met-RANTES (human) acetate reduces bone destruction and ameliorates rats adjuvant-induced arthritis (AIA).

HY-P1034

DAPTA	Inhibitor	99.85%
DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5, and shows potent anti-HIV activities.

HY-17377

Vicriviroc maleate	Antagonist	99.91%
Vicriviroc maleate (SCH-417690 maleate; SCH-D maleate) is a potent, selective, oral bioavailable and CNS penetrated antagonist of CCR5, with a K_i of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with IC₉₀s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU?570).

HY-101713

Ilacirnon	Inhibitor	99.87%
CCX140 (CCX140-B) is a potent CCR2 antagonist.

HY-19974

TAK-220	Antagonist	99.95%
TAK-220 is a selective and orally bioavailable CCR5 antagonist, with IC₅₀s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK-220 also selectively inhibits HIV-1, with EC₅₀s of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), and 0.55 nM (HIV-1 HHA), and EC₉₀s of 12 nM (HIV-1 KK), 5 nM (HIV-1 CTV), 12 nM (HIV-1 HKW), 28 nM (HIV-1 HNK), 15 nM (HIV-1 HTN), and 4 nM (HIV-1 HHA) in PBMCs.

HY-17450A

Aplaviroc hydrochloride	Antagonist	99.93%
Aplaviroc (AK 602) hydrochloride, a SDP derivative, is a CCR5 antagonist, with IC₅₀s of 0.1-0.4 nM for HIV-1_Ba-L, HIV-1_JRFL and HIV-1_MOKW.

HY-119101

AZD-5672	Antagonist
AZD-5672 is an orally active, potent, and selective CCR5 antagonist (IC₅₀=0.32 nM). AZD-5672 shows moderate activity against the hERG ion channel (binding IC₅₀=7.3 μM). AZD5672 is a substrate of human P-gp, and inhibits P-gp-mediated digoxin transport (IC₅₀=32 μM). AZD-5672 can be used for the research of rheumatoid arthritis.

HY-117621

PF-04634817	Antagonist	98.87%
PF-0463481 is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC₅₀=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC₅₀=470 nM). PF-0463481 is safe and well-tolerated and has the potential for the study of diabetic nephropathy.

HY-111069

Nifeviroc	Inhibitor	98.17%
Nifeviroc is an orally active CCR5 antagonist. Nifeviroc is used for the study of HIV type-1 infection.

HY-P4191

Met-RANTES (human)	Antagonist
Met-RANTES (human) is the antagonist for CCR1 and CCR5. Met-RANTES (human) inhibits chemokines human MIP-1α and MIP-1β with IC₅₀ of 5 and 2 nM. Met-RANTES (human) reduces bone destruction and ameliorates rats adjuvant-induced arthritis (AIA).

HY-17450

Aplaviroc	Antagonist
Aplaviroc (AK 602), a SDP derivative, is a CCR5 antagonist, with IC₅₀s of 0.1-0.4 nM for HIV-1_Ba-L, HIV-1_JRFL and HIV-1_MOKW.

HY-117621A

PF-04634817 succinate	Antagonist	99.50%
PF-0463481 succinate is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC₅₀=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC₅₀=470 nM). PF-0463481 succinate is safe and well-tolerated and has the potential for the study of diabetic nephropathy.

HY-152132

CCR5 antagonist 3	Inhibitor
CCR5 antagonist 3 (Compound 26) is a CCR5 antagonist with an IC₅₀ of 15.90 nM. CCR5 antagonist 3 shows broad-spectrum anti-HIV-1 activities.

Name
Email *

	Sorry, but the email address you supplied was invalid.

CCR5 Related Products (27)